Tetracycline-responsive element 3rd-generation (TRE3G) promoter

Re-engineered tetracycline response element combining seven tet operator repeats with an evenly spaced, randomized operator sequence upstream of a minimal CMV promoter. Has no activity on its own; requires co-expression of a compatible Tet-On/Tet-Off transactivator (rtTA/tTA) to activate transcription. The operator redesign removes near-palindromic binding sites for endogenous mammalian transcription factors, substantially lowering background expression compared to the original TRE.

Length: 376 bp

Strength: inducible

Tissue: None inherent — determined by the promoter driving the co-expressed tTA/rtTA transactivator

Expression: inducible

Origin: Synthetic — re-engineered 7x tetO array + minimal CMV promoter

Characteristics

Retains seven tandem copies of the 19-bp tet operator upstream of a minimal CMV promoter, as in the original TRE, but changes operator spacing from 42 nt to an even 36 nt and randomizes the spacer sequence to remove near-palindromic sites that bind endogenous mammalian transcription factors. In transient transfection assays this reduces basal (uninduced) reporter expression more than 100-fold relative to the original TRE promoter while preserving comparable induced expression, giving on/off regulation ranges up to roughly 50,000-fold; after retroviral transduction, background expression is reduced about 15-fold relative to the original TRE, widening the regulation range roughly 30-fold (Loew et al. 2010).

Applications: Used as the responsive promoter in Tet-On 3G and related doxycycline-inducible expression systems — retroviral and lentiviral vectors, stable cell lines, and transgenic constructs — where minimized background expression in the uninduced state is required, such as conditional transgene, shRNA, or CRISPR-component expression.

Limitations: Like the original TRE, has no activity on its own and requires co-expression of a compatible transactivator (e.g., an evolved Tet-On 3G rtTA) in the same cell, adding a second genetic component to any construct. The reduced-background improvements were characterized in transient transfection and retroviral-transduction assays (Loew et al. 2010); performance in other delivery contexts should be confirmed experimentally.

Sequence

You must be signed in to view the full sequence.

References

  1. Loew et al. (2010). Improved Tet-responsive promoters with minimized background expression. BMC Biotechnol - Loew 2010 TRE3G Optimization